Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAGLE: Inhaled Nitric Oxide to Predict Wean Success in PAH
NCT02436512Phase 3Withdrawn
- Sponsor
- Genomatica
- Start
- Jun 2015
- Primary completion
- Aug 2015
- Modality
- Transdermal Patches, Inhalation Devices, Hydrogel Systems
- Countries
- 1
01
Overview
A Phase 3 trial of Nitric oxide-releasing solution in pulmonary arterial hypertension (PAH), sponsored by Genomatica. Planned start Jun 2015; status: withdrawn.
02
Drugs
Nitric oxide-releasing solution
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02436512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02436512.